Journal of Medicines Development Sciences

Editor-in-ChiefBoeynaems, Jean-Marie

ISSN: 2382-6371 (Online)

ISSN: 2382-6363 (Print)

Journal Abbreviation: J Med Dev Sci

Article Processing Charges (APC): Click here for more details

Publishing Model: Open Access

Journal no: 1P

About the Journal

The Journal of Medicines Development Sciences focuses on the discovery and development of new medicinal products. The journal publishes original research articles on medicinal chemistry, experimental pharmacology including pharmacokinetics, preclinical safety, clinical pharmacology, pharmacogenomics, clinical research, pharmacoepidemiology and pharmacoeconomics. The journal also publishes brief reports on new research findings and review articles. Articles encouraging taking the therapy from bench to bedside and creating a broad readership of young researchers, clinicians and scientists are welcome.

Recently Published Articles

Position Article

Alan Boyd, Peter Stonier, Konrad Obiora, Ben Cottam
40 Views, 142 PDF Downloads

The Faculty of Pharmaceutical Medicine was established in the United Kingdom (UK) in 1989 to develop and maintain competence, ethics and the highest professional standards of practice in the discipline. This article charts the founding principles and history of the Faculty, details its composition and membership, and outlines the major functions and achievements of the organisation in the context of the development of the discipline of pharmaceutical medicine. The recognition of pharmaceutical medicine as a medical specialty in the UK is described together with the associated certification programme Pharmaceutical Medicine Specialty Training, which enables pharmaceutical physicians to become certified practitioners in the specialty with the UK General Medical Council (UK GMC).

PDF

Review Article

Akiko Kishi, Ichiro Uchida, Daisuke Koide, Kyoko Imamura
40 Views, 62 PDF Downloads

Development of new medicines has become increasingly difficult with less possibility of success in seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection also erodes social trust in clinical development. In order to develop competence of professionals in medicines development such as clinical investigators and drug development scientists, a variety of educational courses and training programs have been developed and executed worldwide. As Japan is no exception and shares the same concerns, significant governmental and non-governmental efforts have been made to invest in the development of academic educational courses and adherence to international standards. This article introduces examples of the adoption of technologies to realize a user-friendly and sustainable learning management as well as an adaptation of syllabuses and core curricula to meet international standards in the era of global medicines development.

PDF

Conference Highlights

Dipak Kalra, Mats Sundgren, Brecht Claerhout, Pierre Meulien, Bart Vannieuwenhuyse, Peter Singleton, Terje Peetso, Veli Stroetmann, Petra Wilson, Mary Baker, Pascal Coorevits, John O’Brien, Georges De Moor
31 Views, 50 PDF Downloads

The European Institute for Innovation through Health Data (i~HD) has been formed as one of the sustainable entities arising from the Electronic Health Records for Clinical Research (EHR4CR) and SemanticHealthNet projects, in collaboration with other European Commission projects and initiatives. The vision of i~HD is to become the European organisation of reference for guiding and catalysing the best, most efficient and trustworthy uses of health data and interoperability, for optimizing health and knowledge discovery.

i~HD has been established in recognition that there is a need to tackle areas of challenge in the successful scaling up of innovations that rely on high-quality and interoperable health data, to sustain and propagate the results of eHealth research, and to address current-day obstacles to using health data. i~HD was launched at an inaugural conference in Paris, in March 2016. This was attended by over 200 European clinicians, healthcare providers and researchers, representatives of the pharma industry, patient associations, health professional associations, the health ICT industry and standards bodies. The event showcased issues and approaches, that are presented in this paper to highlight the activities that i~HD intends to pursue as enablers of the better uses of health data, for care and research.

PDF

Review Article

Anita Aperia, Jorgen Dirach, Mike Hardman, Christa Janko, Jeff Kipling, Rosan Kreeftmeijer-Vegter, Rebecca Ludwig, Lena Scott, Armel Stockis
50 Views, 46 PDF Downloads

“No research without trained researchers” has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects. However, it is often hard to determine the type of training required at different stages of a scientist’s career. The situation is further complicated by the constantly changing environment, e.g. the growth of disruptive technologies, societal expectations of biomedical sciences, the greater need for multi-disciplinary collaborations, and conservative or changing regulatory requirements. This article summarises the experience from a series of five EMTRAIN Public Private Partnership PhD workshops that included both scientific and transferrable skill training. This is followed by an example of a recently developed training programme, including a competency profile, for translational research and medicines development; the C-COMEND teaching programme. The emphasis is on competencies as a new currency for continuing professional development. Finally, this paper describes what we consider to be the next steps required by the scientific community to address solutions to the current training challenges so that society can benefit from the innovations that only science can provide.

PDF

Original Research Article

Ana Paula Ruenis, João Massud Filho
80 Views, 98 PDF Downloads
Brazil is one of the world´s largest economies and pharmaceutical markets, having the Brazilian government as an important purchaser. There are strong local companies that have grown sustainably after the introduction of generics and are investing in both incremental and radical innovation. However, research and development (R&D) expenditures are still modest; this could be explained by a combination of economic and political uncertainty in the past few years and a bureaucratic, complex regulatory framework. New regulations, efforts to reduce ethical and regulatory review timelines, and a Senate bill aimed to accomplish that goal should constitute the definitive regulatory landmark for boosting clinical research. In addition to government investments they have given a breath of relief in the market, as Brazil is trying to, once again, gain momentum as a “must-go” country for clinical development. Non-profit associations such as the Brazilian Society of Pharmaceutical Medicine (Sociedade Brasileira de Medicina Farmacêutica-SBMF), the Brazilian Association of CROs (Associação Brasileira de Organizações Representativas de Pesquisa Clínica-ABRACRO), the Brazilian Clinical Research Alliance (Aliança Pesquisa Clínica Brasil), amongst others, helped to give the impulse to trigger such changes. It is time to invest heavily in developing educational programs to address the growing need for clinical development scientists and physicians.
PDF

Original Research Article

Victoria Elegant
88 Views, 179 PDF Downloads

The Asia Pacific region is an extremely diverse region, characterized by heterogeneity from a number of aspects, including culture, religion, economics, landscapes, and languages. This also applies to the standard of medical care and the regulatory requirements for approval of drugs in the region. Developed economies such as Japan and Australia have requirements which are not dissimilar to those of the EU and USA, but still have their own unique requirements. The developing economies all have their own requirements. In the ASEAN region there is harmonization of the dossier format, but each country still has local requirements. The region has seen significant growth in clinical trial activity, both to satisfy local registration and safety requirements and to help accelerate global trial patient recruitment. There is a clear need for training in all aspects of medical, regulatory, clinical and safety aspects of medicines development, which is being addressed through several organizations and at different locations in the region.

PDF

Original Research Article

Elyse I. Summers
69 Views, 78 PDF Downloads
This year marks the 15th anniversary of the founding of the Association for the Accreditation of Human Research Protection Programs (AAHRPP), an organization that has been instrumental in strengthening protections for research participants. AAHRPP was established by seven Founding Members in response to a series of high-profile incidents that shook the foundation of the U.S. research enterprise. The Founding Members viewed voluntary accreditation as one way to strengthen research protections and restore and preserve public trust. Today, AAHRPP accreditation is widely regarded as the gold standard for research protections. To attain accreditation, organizations must demonstrate that they adhere to rigorous standards covering three domains: The Organization, The Institutional Review Board or Ethics Committee, and Researcher and Research Staff. The emphasis is on system-wide policies and procedures that strengthen an organization’s commitment to participants and help ensure a more consistent, more effective approach to protecting them. Because AARHPP accreditation is considered an objective indicator of quality, the benefits to accredited organizations can be considerable. Their accreditation status sends a signal — to potential research partners, to sponsors and other funders, and to research participants — that the organization has the systems in place to conduct research in a scientifically and ethically sound manner.
PDF

Review Article

Dorothée Cammarata, Abduelhakem Ben Addi, Eva D’Amico, Bernard Robaye
100 Views, 88 PDF Downloads
Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y6 receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y6 receptor in the adaptive immune response remains unclear. In this study, we demonstrate that the P2Y6 receptor is functionally expressed in murine bone marrow dendritic cells (BMDC). UDP induced a Ca2+ transient in these cells that was decreased in P2Y6-deficient mice. UDP also increased the endocytosis of fluorescein isothiocyanate-dextran (FITC-dextran) and amplified the secretion of interleukin 12-p70 (IL-12p70) induced by CpG; these responses were abolished in P2Y6-deficient mice. In vivo experiments showed that the serum level of specific IgG2c after immunisation with ovalbumin was decreased in P2Y6-deficient mice, while the level of specific IgG1 was unchanged. These data suggest that the P2Y6-mediated effects of UDP on myeloid dendritic cells play a role in the in vivo Th1 skewing of the immune response.
PDF

Review Article

Franck Atienzar, Annie Delaunois, Frédéric Brouta, Miranda Cornet, Renaud Fleurance, Helga Gerets, Stéphanie Glineur, Catrin Hasselgren, Andrea Kiessling, Andre Nogueira da Costa, Marie-Luce Rosseels, Karen Tilmant, Jean-Pierre Valentin
361 Views, 249 PDF Downloads
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are the leading reasons. Reducing attrition rate can be achieved by various means, starting with a comprehensive evaluation of the potential safety issues associated to the primary target followed by an evaluation of undesirable secondary targets. To address these risks, a risk mitigation plan should be built at very early development stages, using a panel of in silico, in vitro, and in vivo models. While most pharmaceutical companies have developed robust safety strategies to de-risk genotoxicity and cardiotoxicity issues, partly driven by regulatory requirements; safety issues affecting other organs or systems, such as the central nervous system, liver, kidney, or gastro-intestinal system are less commonly addressed during early drug development. This paper proposes some de-risking strategies that can be applied to these target organ systems, including the use of novel biomarkers that can be easily integrated in both preclinical and clinical studies. Experiments to understand the mechanisms’ underlying toxicity are also important. Two examples are provided to demonstrate how such mechanistic studies can impact drug development. Novel trends in investigative safety are reviewed, such as computational modeling, mitochondrial toxicity assessment, and imaging technologies. Ultimately, understanding the predictive value of non-clinical safety testing and its translatability to humans will enable to optimize assays in order to address the key objectives of the drug discovery process, i.e., hazard identification, risk assessment, and mitigation.
PDF

Editorial

Jean-Marie Boeynaems
71 Views, 41 PDF Downloads
Welcome to the 3rd issue of the Journal of Medicines Development Sciences. Like previous issues it contains articles covering the entire process of drug development from target identification to drug registration.
PDF
Read more

Indexing and Archiving

Journal of Medicines Development Sciences (JMDS) aims to be indexed by world-recognized databases, for example, PubMed, Scopus and Science Citation Index (SCI). SOM has been indexed and archived by several databases:

Editorial Board

Editor-in-Chief

Jean Marie BoeynaemsUniversité Libre de BruxellesBelgium

Associate Editors

Kazuhide InoueKyushu UniversityJapan
Sandor Kerpel-FroniusSemmelweis UniversityHungary
Bernd RosenkranzStellenbosch UniversitySouth Africa
Jean-Pierre ValentinUCB PharmaBelgium

Editorial Board Members

Abdelilah AboussekhraKing Faisal Hospital & Research CentreSaudi Arabia
Ronald BarbarasCerenis TherapeuticsFrance
Dominique DuboisPatient Value Solutions (PVS) ConsultancyBelgium
Vincent DupriezPerkin-Elmer Life SciencesBelgium
Alison GartlandUniversity of SheffieldUnited Kingdom
Michel GillardUCB PharmaBelgium
Schuichi KoizumiUniversity of YamanashiJapan
Eduardo LazarowskiUniversity of North CarolinaUnited States
Jesus PintorComplutense University of MadridSpain
Sam SalekInstitute for Medicines DevelopmentUnited Kingdom
Eckart SchwarzGSKUnited States
Honorio SilvaIFAPPUnited States
David VermijlenUniversité Libre de BruxellesBelgium
Zeynep OzdemirInonu UniversityTurkey
NeelabhBanaras Hindu UniversityIndia

Focus and Scope

The Journal of Medicines Development Sciences focuses on the discovery and development of new medicinal products. The journal publishes original research articles on medicinal chemistry, experimental pharmacology including pharmacokinetics, preclinical safety, clinical pharmacology, pharmacogenomics, clinical research, pharmacoepidemiology and pharmacoeconomics. The journal also publishes brief reports on new research findings and review articles. Articles encouraging taking the therapy from bench to bedside and creating a broad readership of young researchers, clinicians and scientists are welcome.

For Authors

  • A manuscript would not be accepted if it has been published or is currently under consideration for publication in any other journals. The author will need to notify the editorial team if the data in their submission has been presented in conferences.

  • Authorship should be limited to people who have contributed substantially to the work. Authors must indicate their specific contributions to the published work. This information should be listed in the manuscript under the section ‘Author Contribution’. Examples of contributions include: designed research, performed research, contributed new reagents or analytic tools, analyzed data, wrote the paper.

    For more information on submission’s format, please refer to the ‘Author Guidelines’ link accessible from the ‘About’ button at the top row of this page.

    The corresponding author should be clearly indicated for all manuscripts submitted. A maximum of two corresponding authors are allowed for the responsibilities associated. The corresponding author(s) is responsible for:

    • Obtaining permission from all the authors mentioned in the manuscript
    • Ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication
    • Including written permission from the authors of the work concerned for any mention of any unpublished material included in the manuscript, e.g. data from manuscripts-in-press, personal communication, or work in preparation.
  • The author has to provide the authorization of no conflict with any financial body or funding agency that might influence the results or interpretation of their manuscript. All authors, members, reviewers and editors must disclose any association that poses a conflict of interest in connection with the manuscript. The corresponding author will be asked to sign a form behalf of all of the authors regarding potential conflicts of interest at the time of acceptance.

  • The editorial team does not approve of any plagiarism attempts. iThenticate will be utilized at the editor’s discretion to verify the originality of submitted manuscripts. If plagiarism is detected during the review process the manuscript may be rejected pending the severity of plagiarism. Therefore, if a manuscript uses a text copied directly from another source, this text must be written in quotation marks and the original source must be cited.

  • All articles must be written in English — preferably American English. SI units should be used. If you are not a native English speaker, you may want to utilize an external or Whioce Publishing’s optional professional language editing service before submitting the final version.

  • Whioce Publishing Pte Ltd offers its own professional editing services. By using this service, you can be sure that your English-language manuscript will be polished and ready for submission to your publication of choice at a very reasonable price. For further details about the Language Editing Services, please contact us at editorial@whioce.com. Please note that utilizing a language editing service is not a guarantee of acceptance.

  • Revised manuscripts must contain a detailed point by point response to the comments of the reviewers. The response to reviewers has to be uploaded as a separate file.

  • If you withdraw your manuscript after it has been accepted (but not yet published), you will be charged for costs incurred at USD200.

  • Authors are expected to have minimum amount of post-acquisition processing of data. In case of processing; alterations must be applied to the entire image (e.g., brightness, contrast, color balance). Any kind of alteration if being done has to be clearly stated in the figure legend and in Methods section.

    Grouping of data (e.g., cropping of images of removal of lanes from gels and bolts) must be made apparent and should be explicitly indicated in the appropriate figure legends. Data comparisons should only be made from comparative experiments, and individual data should not be utilized across multiple figures. If inappropriate image/data manipulation is identified after publication, we reserve the right to ask for the original data and, if that is not satisfactory, to issue a correction or retract the paper, as appropriate.

  • Whioce Publishing will preserve e-journals with Portico, ensuring that they will be secure and available into the future.

  • Author Guidelines

    Before submitting for publication, please check that your manuscript has been prepared in accordance to the step-by-step instructions for submitting a manuscript to our online submission system.

    Manuscript Format

    Your manuscript should be in MS Word or LaTeX format. You are advised to download the template when preparing your submissions to this journal. All manuscripts must be written in clear, comprehensible English. Both British and American English are accepted. Usage of non-English words should be kept to a minimum and all must be italicized, with the exception of “e.g.” and “i.e.” If you have concerns about the level of English in your submission, please ensure that it is proofread before submission by a native English speaker or a scientific editing service.

    Types of submission accepted:

    International Journal of Bioprinting accepts original articles, reviews, letters, editorials, commentaries, perspectives and position papers. Please read this section further for the definition of each type and select the appropriate option in the submission system. Submissions exceeding the suggested requirements, such as total manuscript length, will still be processed for consideration and peer review. However, article processing charges will differ in exceptional cases (e.g. a raw text file exceeding 2MB, etc.) The article processing charge will then be determined on a case-by-case basis.

    Original articles: Scientific articles on original basic and applied research and/or analysis. This manuscript type typically has 5 tables and figures in total, and has approximately 40 references and 7,000 words (inclusive of reference list and abstract).

    Review articles: A summary highlighting recent developments and current/future trends of the field. This manuscript type typically has 5 tables and figures in total, with approximately 70 references and 7,000 words (inclusive of reference list and abstract).

    Letters to the Editor-in-Chief/authorship (please specify): Comments from reader(s) about individual articles. These letters must be constructive and contribute to the development of individual articles published or the entire journal. Letters containing new ideas, supporting data or data criticizing an article may be subjected to peer-review (determined on a case-by-case basis by the journal’s editorial team) and published in the online publication but not in the printed version. This manuscript type typically has 1,800 words (exclusive of reference list).

    Editorials: Solicited concise commentary highlighting prominent topics in the Journal’s issue. These are the official opinions of the editors of the journal or its special issue. Editorials will be published in both online and printed versions of the journal. This manuscript type typically has 3,500 words.

    Commentaries: Unsolicited commentaries or analysis from reader(s) targeting specific published articles in the journal. Commentaries will be subjected to peer-review and may be published in both online and printed versions of the journal. This manuscript type typically has 3,500 words.

    Perspectives: These are author’s personal opinion on a subject/topic. Unlike Reviews, Perspective articles may cover a more specific, narrow part of the field. However, these are still required to uphold the spirit of academia of being objective as well as aiming to initiate or furthering discussions and novel experimental procedures in the field. Therefore, it will undergo peer review and be indexed if accepted. Accepted articles may be solicited or unsolicited. This manuscript type typically has 5 tables and figures in total, along with approximately 70 references and 7,000 words (inclusive of reference list and abstract).

    Reports: Documents that summarize the execution and results of a clinical case involving bioprinted construct or a collaborative research programme that is directly related to the advancement of bioprinting. Submissions will be evaluated on a case-by-case basis and are usually solicited by the editors.

    Position papers: Submissions that reflect the official opinion of an organization (e.g. government bodies, funding agencies, etc.) This manuscript type typically has 3,500 words.

    Cover letter

    All submissions should include a cover letter as a separate file. A cover letter should contain a brief explanation of what was previously known, the conceptual advancement with the findings and its significance to broad readership. The cover letter is confidential and will be read only by the editors. It will not be seen by reviewers.

    Title

    The title should capture the conceptual significance for a broad audience. The title should not be more than 50 words and should be able to give readers an overall view of the paper’s significance. Titles should avoid using uncommon jargons, abbreviations and punctuation.

    List of Authors

    The names of authors must be spelled out rather than set in initials along with their affiliations. Authors should be listed according to the extent of their contribution, with the major contributor listed first. All corresponding authors should be identified with an asterisk. Affiliations should contain the following core information: department, institution, city, state, postal code, and country. For contact, email address of at least one corresponding author must be included. Please note that all authors must view and approve the final version of the manuscript before submitting.

    Abstract

    Articles must include an abstract containing a maximum of 200 words. The purpose of abstract is to provide sufficient information for a reader to determine whether or not to proceed to the full text of the article. After the abstract, please give 5 keywords; please avoid using the same words as those already used in the title.

    Section Headings

    Please number the section headings (e.g. 1234, etc.) in boldface. Likewise, use boldface to identify subheadings too but please distinguish it from major headings using numbers (e.g. 1.11.22.12.2, etc.) Further subsections of subheadings should be differentiated by boldface and italics font with the numbers (1)(2)(3), etc.

    Introduction

    The introduction should provide a background that gives a broad readership an overall outlook of the field and the research performed. It tackles a problem and states its important regarding with the significance of the study. Introduction can conclude with a brief statement of the aim of the work and a comment about whether that aim was achieved.

    Materials and Methods

    This section provides the general experimental design and methodologies used. The aim is to provide enough detail to for other investigators to fully replicate the results. It is also required to facilitate better understanding of the results obtained. Protocols and procedures for new methods must be included in detail for the reproducibility of the experiments. Informed consent should be obtained from patients or parents before the experiments start and should be mentioned in this section.

    Ethics

    Ethics information include IACUC permit numbers and/or IRB name, if applicable. This information should be included in a subheading labelled "Ethics Statement" in the "Methods" section of the manuscript file, in as much detail as possible.

    Results

    This section can be divided into subheadings and focuses on the results of the experiments performed.

    Discussion

    This section should provide the significance of the results and identify the impact of the research in a broader context. It should not be redundant or similar to the content of the results section.

    Conclusion

    Please use the conclusion section for interpretation only, and not to summarize information already presented in the text or abstract.

    Conflict of Interest

    All authors are required to declare all activities that have the potential to be deemed as a source of competing interest in relations to their submitted manuscript. Examples of such activities could include personal or work-related relationships, events, etc. Authors who have nothing to declare are encouraged to add "No conflict of interest was reported by all authors" in this section.

    Funding

    Authors should declare all financial and non-financial support that have the potential to be deemed as a source of competing interest in relations to their submitted manuscript in this section. Financial supports are generally in the form of grants, royalties, consulting fees and others. Examples of non-financial support could include the following: externally-supplied equipment/biological sources, writing assistance, administrative support, contributions from non-authors, etc.

    Appendix

    This section is optional and is for all materials (e.g. advanced technical details) that has been excluded from the main text but remain essential to the readers in understanding the manuscripts. This section is not for supplementary figures. Authors are advised to refer to the section on Supplementary Figures for such submissions.

    Text

    The text of the manuscript should be in Microsoft Word or Latex. The length of the manuscript cannot be more than 50,000 characters (inclusive of spaces), or approximately 7,000 words.

    Nomenclature for genes and proteins

    This journal aims to reach researchers all over the globe. Hence, for reviewers’ and readers’ ease in comprehension, authors are highly encouraged to use the appropriate gene and protein nomenclature. Authors may prefer to utilize resources such as http://www.ncbi.nlm.nih.gov/gene.

    Figures

    Authors should include all figures into the manuscript and submit it as one file. Figures include photographs, scanned images, graphs, charts and schematic diagrams. Figures submitted should avoid unnecessary decorative effects (e.g. 3D graphs), as well as should be minimally processed (e.g. changes in brightness and contrast applied uniformly for the entire figure). It should also be set against a white background. Please remember to label all figures (e.g. axis, etc.) and add captions below the figure, as required. These captions should be numbered (e.g. Figure 1Figure 2, etc.) in boldface. All figures must have a brief title (also known as caption) that describes the entire figure without citing specific panels, followed by a legend, defined as description of each panel. Please identify each panel with uppercase letters in parenthesis (e.g. (A), (B), (C), etc.)

    The preferred file formats for any separately submitted figure(s) are TIFF or JPEG. All figures should be legible in print form and of optimal resolution. Optimal resolutions preferred are 300 dots per inch (dpi) for RBG coloured, 600 dpi for greyscale and 1,200 dpi for line art. Although there are no file-size limitation imposed, authors are highly encouraged to compress their figures to an ideal size without unduly affecting the legibility and resolution of figures. This will also speed up the process of uploading in the submission system, if necessary.

    The Editor-in-Chief and Publisher reserve the right to request from author(s) the high-resolution files and unprocessed data and metadata files, should the need arise at any point after manuscript submission for reasons such as production, evaluation or other purposes. The file name should allow for ease in identifying the associated manuscript submitted.

    Tables, lists and equations

    Tables created using Microsoft Word table function are preferred. The tables should include a title at the top. Titles and footnotes/legends should be concise. These must be submitted in the manuscript. Likewise, lists and equations should be properly aligned and its meaning clear to readers. For listing items within the main body of the manuscript, please use Roman numbers in parenthesis (e.g. (i), (ii), (iii), (iv), etc.).

    Supplementary information

    This section is optional and contains all materials and figures that have been excluded from the entire manuscript. These information are relevant to the manuscript but remain non-essential to readers’ understanding of the manuscript’s main content. All supplementary information should be submitted as a separate file in Step 4 during submission. Please ensure the names of such files contain ‘suppl. info’. Videos may be included in this section.

    In-text citations

    Reference citations in the text should be numbered consecutively in superscript square brackets. Some examples:

    1. Negotiation research spans many disciplines[3,4].
    2. This result was later contradicted by Becker and Seligman[5].
    3. This effect has been widely studied[1–3,7].

    Personal communications and unpublished works can only be used in the main text of the submission and are not to be placed in the Reference section. Authors are advised to limit such usage to the minimum. These should also be easily identifiable by stating the authors and year of such unpublished works or personal communications, and the word ‘Unpublished’ in parenthesis.

    E.g. (Smith J, 2000, Unpublished)

    References

    This section is compulsory and should be placed at the end of all manuscripts. Do not use footnotes or endnotes as a substitute for a reference list. The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should be excluded from this section. 

    For the reference list, all authors must be stated. Authors being referenced are listed with their surname followed by their initials. All references should be numbered (e.g. 1, 2, 3, etc.) and sequenced according to the order they appear as the in-text citations. References should follow the following pattern: Author(s), followed by year of publication, title of publication, full journal name in italics, volume number, issue number in parenthesis and lastly, page range. If the referred article has more than three authors, list only the first three authors and abbreviate the remaining authors as the italicized ‘et al.’ (meaning "and others"). If the DOI is available, please include it after the page range. Examples of references for different types of publications are as follows;

    Journal

    Journal article (print) with one to three authors:

    Younger P, 2004, Using the internet to conduct a literature search. Nurs Stand, 19(6): 45–51.

    Journal article (print) with more than three authors:

    Gamelin F X, Baquet G, Berthoin S, et al., 2009, Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol, 105(1): 731–738.

    Journal article (online) with one to three authors:

    Jackson D, Firtko A and Edenborough M, 2007, Personal resilience as a strategy for surviving and thriving in the face of workplace adversity: A literature review. J Adv Nurs, 60(1): 1–9. http://doi.org/10.1111/j.1365-2648.2007.04412.x

    Journal article (online) with more than three authors:

    Hargreave M, Jensen A, Nielsen T S S, et al., 2015, Maternal use of fertility drugs and risk of cancer in children — A nationwide population-based cohort study in Denmark. Int J Cancer, 136(8): 1931–1939. http://doi.org/10.1002/ijc.29235

    Book

    Book with one to three authors:

    Schneider Z, Whitehead D and Elliott D, 2007, Nursing and Midwifery Research: Methods and Appraisal for Evidence-based Practice, 3rd edn, Elsevier Australia, Marrickville, NSW, 112–130.

    Book with more than three authors

    Davis M, Charles L, Curry M J, et al., 2003, Challenging Spatial Norms, Routledge, London, 12–30.

    Chapter or article in book

    Knowles M S, (eds) 1986, Independent study, in Using Learning Contracts, Jossey-Bass, San Francisco, 89–96.

    Others

    Proceedings of meetings and symposiums, conference papers:

    Chang S S, Liaw L and Ruppenhofer J, (eds) 2000, Proceedings of the twenty-fifth annual meeting of the Berkeley Linguistics Society, February 12–15, 1999: General session and parasession on loan word phenomena. Berkeley Linguistics Society, Berkeley, 12–13.

    Conference proceedings (from electronic database):

    Wang T, Cook C and Derby B, 2009, Fabrication of a glucose biosensor by piezoelectric inkjet printing. Proceedings of the Third International Conference on Sensor Technologies and Applications, 2009 (SENSORCOM-
    M’09)
    , 82–85.

    Online document with author names:

    Este J, Warren C, Connor L, et al., 2008, Life in the clickstream: The future of journalism, Media Entertainment and Arts Alliance, viewed May 27, 2009, http://www.alliance.org.au/documents/ foj_report_final.pdf

    Online document without author name:

    Developing an argument, n.d., viewed March 30, 2009, http://web.princeton.edu/sites/writing/Writing_Center/WCWritingResources.htm

    Thesis/Dissertation:

    Gale L, 2000, The relationship between leadership and employee empowerment for successful total quality management, thesis, Australasian Digital Thesis database, University of Western Sydney, 110–130.

    Standards:

    Standards Australia Online, 2006Glass in buildings: selection and installation, AS 1288-2006, amended January 31, 2008, SAI Global database, viewed May 19, 2009.

    Government report:

    National Commission of Audit, 1996, Report to the Commonwealth Government, Australian Government Publishing Service, Canberra.

    Government report (online):

    Department of Health and Ageing, 2008, Ageing and aged care in Australia, viewed November 10, 2008, http://www.health.gov.au/internet/main/publishing.nsf/Content/ageing

    No author:

    Guide to agricultural meteorological practices, 1981, 2nd edn, Secretariat of the World Meteorological Organization, Geneva, 10–20.

    Note: When referencing an entry from a dictionary or an encyclopedia with no author there is no requirement to include the source in the reference list. In these cases, only cite the title and year of the source in-text. For an authored dictionary/encyclopedia, treat the source as an authored book.

  • The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Article Processing Charges (APC)

Journal of Medicines Development Sciences is an Open Access Journal under Whioce Publishing. All articles published in Journal of Medicines Development Sciences are accessible electronically from the journal website without commencing any kind of payment. In order to ensure contents are freely available and maintain publishing quality, Article Process Charges (APC) is applicable to all authors who wish to submit their articles to the journal to cover the cost incurred in processing the manuscripts. Such cost will cover the peer-review, copyediting, typesetting, publishing, content depositing and archiving processes. Those charges are applicable only to authors who have their manuscript successfully accepted after peer-review.

Journal TitleAPC
Journal of Medicines Development Sciences$800

We encourage authors to publish their papers with us and don’t wish the cost of article processing fees to be a barrier especially to authors from the low and lower middle income countries/regions. A range of discounts or waivers are offered to authors who are unable to pay our publication processing fees. Authors can write in to apply for a waiver and requests will be considered on a case-by-case basis.

Authors based in these countries/regions listed below may apply to receive up to a 50%-100% waiver of the standard article processing fee; Waiver subjected to approval.

  • Afghanistan
  • Armenia
  • Bangladesh
  • Benin
  • Bhutan
  • Bolivia
  • Burkina Faso
  • Burundi
  • Cabo Verde
  • Cambodia
  • Cameroon
  • Central African Republic
  • Chad
  • Comoros
  • Congo, Dem. Rep
  • Congo, Rep.
  • Côte d'Ivoire
  • Djibouti
  • Egypt, Arab Rep.
  • El Salvador
  • Eritrea
  • Ethiopia
  • Gambia, The
  • Ghana
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Haiti
  • Honduras
  • India
  • Indonesia
  • Kenya
  • Kiribati
  • Korea, Dem. People's Rep.
  • Kosovo
  • Kyrgyz Republic
  • Lao PDR
  • Lesotho
  • Liberia
  • Madagascar
  • Malawi
  • Mali
  • Mauritania
  • Micronesia, Fed. Sts.
  • Moldova
  • Mongolia
  • Morocco
  • Mozambique
  • Myanmar
  • Nepal
  • Nicaragua
  • Niger
  • Nigeria
  • Pakistan
  • Papua New Guinea
  • Philippines
  • Rwanda
  • Samoa
  • São Tomé and Principe
  • Senegal
  • Sierra Leone
  • Solomon Islands
  • Somalia
  • South Sudan
  • Sri Lanka
  • Sudan
  • Swaziland
  • Syrian Arab Republic
  • Tajikistan
  • Tanzania
  • Timor-Leste
  • Togo
  • Tonga
  • Tunisia
  • Uganda
  • Ukraine
  • Uzbekistan
  • Vanuatu
  • Vietnam
  • West Bank and Gaza
  • Yemen, Rep.
  • Zambia
  • Zimbabwe

If you are residing in one of the above mentioned countries and need to apply for a waiver, please email our editorial department (editorial@whioce.com) with the following information:

  • Your name and institution with full address details
  • Title of journal you wish to submit a manuscript to
  • Reason for applying for a waiver
  • Title of your paper
  • Country of residence of all co-author

APC Payment

Payments for APC of this journal can be made through our online PayPal payment gateway. Enter the article no. into the below textbox and select "Pay Now" to proceed with payment.

Article No.

*Article No. is mandatory for payment and it can be found on the acceptance letter issued by the Editorial Office. Payment without indicating Article No. will result in processing problem and delay in article processing. Please note that payments will be processed in USD. You can make payment through Masters, Visa or UnionPay card.

Frequently Asked Questions

  • Answer: To establish whether your paper is suitable for this journal, please read Focus and Scope under Editorial Policies.
  • Answer: Registration and login are required to submit manuscript online and to check the status of current submission.
  • Answer: The submission file can be submitted in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
  • Answer: The length of the manuscript cannot be more than 8000 words.
  • Answer: The cover letter is necessary for each submission. The cover letter should be uploaded as a separate file in Step 4 during the submission. The contents of the cover letter should include brief explanation of what was previously known, the conceptual advancement with the findings and its significance to broad readership. The cover letter will only be visible to the editor. Reviewers will not have access to the cover letter.
  • Answer: You can suggest 2 reviewers for your submission. However, the decision of whether to invite them lies with the Editor.
  • Answer: This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Refer to the Publication Fees tab for more details.

Announcements

 

Call for Papers

 

The Editor-in-Chief, Prof. Jean-Marie Boeynaems, invites all authors to submit manuscripts for peer-review.

The Journal of Medicines Development Sciences (JMDS) focuses on the discovery and development of new medicinal products. The journal publishes original research articles on medicinal chemistry, experimental pharmacology including pharmacokinetics, preclinical safety, clinical pharmacology, pharmacogenomics, clinical research, pharmacoepidemiology and pharmacoeconomics. The journal also publishes brief reports on new research findings and review articles. Articles encouraging taking the therapy from bench to bedside and creating a broad readership of young researchers, clinicians and scientists are welcome.

JMDS is currently indexed in JournalTOCs. Besides, articles published in JMDS can be searched in Scilit, CNKI Scholar and Google Scholar. JMDS is archived by Portico and the National Library Board of Singapore.

Why Publish With Us?

  • Universal access and visibility of research results
  • Submitted articles are peer-reviewed by a global list of reviewers
  • Authors maintain the copyright to the published articles
  • Authors from low and lower middle income countries who are unable to pay the publication charges can write in to apply for a waiver through editorial@whioce.com
 
Posted: 2017-08-18
 
More Announcements...